This is a competitive renewal application for training grant support in pediatric oncology. The goal of this T32 program is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research and who will work to reduce the burden of cancer in the pediatric population. To accomplish this goal we have engaged a diverse and outstanding training faculty that embraces multiple areas of basic (wet bench), translational and clinical research. This experienced and highly accomplished group includes members of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), the Division of Pediatric Hematology/Oncology at Boston Children's Hospital (BCH), and additional components of the Harvard Medical School (HMS). Particular emphasis is placed on close mentorship of trainees in the selection of mentors and in on-going oversight during their research. The T32 program provides training in oncology research at the postdoctoral level for 8 trainees, selected from the combined DFCI-BCH pediatric hematology/oncology fellowship program, who are in their second, third and fourth years of training. The program is committed to identifying and supporting the most promising fellows, including minority candidates. Over the past 45 years the DFCI-BCH fellowship program has trained over 200 individuals, many of whom are leaders of academic pediatric hematology/oncology programs. Continued T32 support will ensure the training of investigational pediatric oncologists, whose research will contribute immeasurably to the understanding and management of childhood cancers.

Public Health Relevance

While great strides have been made in the diagnosis and treatment of pediatric cancers, much remains to be done. Cure of patient is often achieved with unacceptable side-effects, and for many solid tumors current therapy is inadequate. The best hope for reducing the burden of pediatric cancer is the training of committed researchers by an experienced and accomplished faculty that is involved in diverse aspects of basic and clinical research directly relevant to tackling these challenging problems in children.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Perkins, Susan N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Guenther, Lillian M; Dharia, Neekesh V; Ross, Linda et al. (2018) A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. Clin Cancer Res :
Stolte, Björn; Iniguez, Amanda Balboni; Dharia, Neekesh V et al. (2018) Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma. J Exp Med 215:2137-2155
Ng, Samuel Y; Yoshida, Noriaki; Christie, Amanda L et al. (2018) Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun 9:2024
Guerra, Rachel M; Bird, Gregory H; Harvey, Edward P et al. (2018) Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer. Cell Rep 24:3393-3403.e5
Chen, Liying; Alexe, Gabriela; Dharia, Neekesh V et al. (2018) CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest 128:446-462
Greenzang, Katie A; Cronin, Angel M; Kang, Tammy et al. (2018) Parent understanding of the risk of future limitations secondary to pediatric cancer treatment. Pediatr Blood Cancer 65:e27020
Marron, Jonathan M; Jones, Emma; Wolfe, Joanne (2018) Is There Ever a Role for the Unilateral Do Not Attempt Resuscitation Order in Pediatric Care? J Pain Symptom Manage 55:164-171
Greenzang, Katie A; Dauti, Angela; Mack, Jennifer W (2018) Parent perspectives on information about late effects of childhood cancer treatment and their role in initial treatment decision making. Pediatr Blood Cancer 65:e26978
Ozuah, Nmazuo W; Marcus, Karen J; LaCasce, Ann S et al. (2018) Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. J Pediatr Hematol Oncol 40:e338-e342
Marron, Jonathan M; Cronin, Angel M; Kang, Tammy I et al. (2018) Intended and unintended consequences: Ethics, communication, and prognostic disclosure in pediatric oncology. Cancer 124:1232-1241

Showing the most recent 10 out of 22 publications